



BAVARIAN NORDIC

Company Announcement no. 21 / 2015

Bavarian Nordic Announces the Resignation of James B. Breitmeyer as EVP and Chief Development Officer

COPENHAGEN, Denmark - August 5, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that James B. Breitmeyer, M.D. Ph.D., has today resigned his position as Executive Vice President and Chief Development Officer in the Company due to personal reasons, effective July 31, 2015.

Dr. Breitmeyer served as Executive Vice President of Bavarian Nordic A/S and as a member of its Executive Management since February 2013.

“Jim has led our cancer immunotherapy activities since 2013 and many important achievements have been made under his leadership, including the completion of enrolment in the PROSPECT Phase 3 trial, and the PROSTVAC partnering deal. We thank Jim for his contributions to the company, however we respect his decision and wish him all the very best for the future,” said Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic.

Contacts

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a biopharmaceutical company focused on the development and manufacturing of cancer immunotherapies and vaccines for infectious diseases. Through a long-standing collaboration with the U.S. Government, Bavarian Nordic has developed a portfolio of biological countermeasures, including the non-replicating smallpox vaccine, IMVAMUNE[®], which is stockpiled for emergency use by the U.S. and other governments. The vaccine is approved in the EU (under the trade name IMVANEX[®]) and in Canada. Bavarian Nordic and its partner Janssen are pioneering the development of an Ebola vaccine, which has been fast-tracked by authorities in response to the current situation in West Africa. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies based on its versatile pox-virus based technologies, including PROSTVAC[®], which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter [@bavariannordic](https://twitter.com/bavariannordic).

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.